Your browser doesn't support javascript.
loading
Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.
Recasens-Zorzo, Clara; Cardesa-Salzmann, Teresa; Petazzi, Paolo; Ros-Blanco, Laia; Esteve-Arenys, Anna; Clot, Guillem; Guerrero-Hernández, Martina; Rodríguez, Vanina; Soldini, Davide; Valera, Alexandra; Moros, Alexandra; Climent, Fina; González-Barca, Eva; Mercadal, Santiago; Arenillas, Leonor; Calvo, Xavier; Mate, José Luís; Gutiérrez-García, Gonzalo; Casanova, Isolda; Mangues, Ramón; Sanjuan-Pla, Alejandra; Bueno, Clara; Menéndez, Pablo; Martínez, Antonio; Colomer, Dolors; Tejedor, Roger Estrada; Teixidó, Jordi; Campo, Elias; López-Guillermo, Armando; Borrell, José Ignacio; Colomo, Luis; Pérez-Galán, Patricia; Roué, Gaël.
Afiliación
  • Recasens-Zorzo C; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
  • Cardesa-Salzmann T; Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona.
  • Petazzi P; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona.
  • Ros-Blanco L; Grup d'Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona.
  • Esteve-Arenys A; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
  • Clot G; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
  • Guerrero-Hernández M; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
  • Rodríguez V; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
  • Soldini D; Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona.
  • Valera A; Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona.
  • Moros A; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
  • Climent F; Pathology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat.
  • González-Barca E; Institut Catalá d'Oncología, Hospital Duran I Reynals, L'Hospitalet de Llobregat.
  • Mercadal S; Institut Catalá d'Oncología, Hospital Duran I Reynals, L'Hospitalet de Llobregat.
  • Arenillas L; Pathology Department, IMIM, Hospital del Mar, Barcelona.
  • Calvo X; Pathology Department, IMIM, Hospital del Mar, Barcelona.
  • Mate JL; Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona.
  • Gutiérrez-García G; Department of Hematology, Hospital Clinic, Barcelona.
  • Casanova I; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona.
  • Mangues R; Grup d'Oncogènesi i Antitumorals, lnstitut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau) and Centro de Investigación Biomédica en Red CIBER-BBN, Barcelona.
  • Sanjuan-Pla A; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona.
  • Bueno C; Grup d'Oncogènesi i Antitumorals, lnstitut d'Investigacions Biomèdiques Sant Pau (IIB-Sant Pau) and Centro de Investigación Biomédica en Red CIBER-BBN, Barcelona.
  • Menéndez P; Hematology Research Group, Health Research Institute La Fe, Valencia.
  • Martínez A; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona.
  • Colomer D; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona.
  • Tejedor RE; Institucio Catalana de Recerca I Estudis Avançats (ICREA), CIBERONC, Barcelona.
  • Teixidó J; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
  • Campo E; Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona.
  • López-Guillermo A; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
  • Borrell JI; Hematopathology Unit, Department of Pathology, Hospital Clinic, Barcelona.
  • Colomo L; Grup d'Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona.
  • Pérez-Galán P; Grup d'Enginyeria Molecular, IQS School of Engineering, Universitat Ramon Llull, Barcelona.
  • Roué G; Division of Hemato-Oncology, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), CIBERONC, Barcelona.
Haematologica ; 104(4): 778-788, 2019 04.
Article en En | MEDLINE | ID: mdl-29954928
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azepinas / Linfoma de Células B Grandes Difuso / Receptores CXCR4 / Sistema de Señalización de MAP Quinasas / Acetamidas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Haematologica Año: 2019 Tipo del documento: Article Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Azepinas / Linfoma de Células B Grandes Difuso / Receptores CXCR4 / Sistema de Señalización de MAP Quinasas / Acetamidas Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Haematologica Año: 2019 Tipo del documento: Article Pais de publicación: Italia